Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.67 |
| ▸ | PPARA | Q07869 | 7/20 | 0.67 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600223 | 1.00 | PPARG (0.67) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL14143310 | 0.90 | PPARG (0.61) | PPARGPPARAMEN1ALDH1A1LMNA | |
| SCHEMBL2718446 | 0.89 | PPARG (0.75) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2718448 | 0.89 | PPARG (0.75) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2719814 | 0.89 | PPARG (0.67) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2719820 | 0.89 | PPARG (0.67) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL5367923 | 0.88 | PPARG (0.73) | PPARGPPARAMEN1ALDH1A1LMNA | |
| SCHEMBL5367917 | 0.88 | PPARG (0.73) | PPARGPPARAMEN1ALDH1A1LMNA | |
| SCHEMBL14143467 | 0.88 | PPARG (0.70) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2717139 | 0.88 | PPARG (0.66) | PPARGPPARACYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | PPARG 126/4885PPARA 31/4885CYP4F2 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.